Pages that link to "Q2459042"
Jump to navigation
Jump to search
The following pages link to ipilimumab (Q2459042):
Displayed 50 items.
- carcinoma (Q33525) (← links)
- melanoma (Q180614) (← links)
- skin cancer (Q192102) (← links)
- myelodysplastic syndrome (Q954625) (← links)
- renal cell carcinoma (Q1164529) (← links)
- cytotoxic T-lymphocyte associated protein 4 (Q2907609) (← links)
- non-small-cell lung carcinoma (Q3658562) (← links)
- metastatic melanoma (Q18975855) (← links)
- Extended dose ipilimumab with a peptide vaccine: immune correlates associated with clinical benefit in patients with resected high-risk stage IIIc/IV melanoma (Q24618690) (← links)
- Ipilimumab, vemurafenib, dabrafenib, and trametinib: synergistic competitors in the clinical management of BRAF mutant malignant melanoma (Q26824310) (← links)
- Review of immune-related adverse events in prostate cancer patients treated with ipilimumab: MD Anderson experience (Q26995499) (← links)
- Systematic review and network meta-analysis of overall survival comparing 3 mg/kg ipilimumab with alternative therapies in the management of pretreated patients with unresectable stage III or IV melanoma (Q26996629) (← links)
- Treatment possibilities of ipilimumab-induced thrombocytopenia--case study and literature review (Q26999394) (← links)
- Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma (Q27005902) (← links)
- Nivolumab plus ipilimumab in advanced melanoma (Q27852310) (← links)
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma (Q27861062) (← links)
- Ipilimumab plus dacarbazine for previously untreated metastatic melanoma (Q28131634) (← links)
- Hepatotoxicity with combination of vemurafenib and ipilimumab (Q28288255) (← links)
- CTLA4 CTLA4::CD28 (Q28371555) (← links)
- The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network (Q28485085) (← links)
- Phase II DeCOG-study of ipilimumab in pretreated and treatment-naïve patients with metastatic uveal melanoma (Q28543960) (← links)
- Yervoy (Q29006706) (← links)
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma (Q29615443) (← links)
- Pembrolizumab versus Ipilimumab in Advanced Melanoma (Q29618134) (← links)
- Nivolumab and ipilimumab versus ipilimumab in untreated melanoma (Q29620657) (← links)
- Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial (Q29620814) (← links)
- Structural basis for cancer immunotherapy by the first-in-class checkpoint inhibitor ipilimumab (Q30274619) (← links)
- The effect of timing of stereotactic radiosurgery treatment of melanoma brain metastases treated with ipilimumab (Q30275086) (← links)
- Sarcoidosis in the setting of combination ipilimumab and nivolumab immunotherapy: a case report & review of the literature (Q30275135) (← links)
- Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial (Q30276649) (← links)
- Adoption of ipilimumab in the United States: a Medicare study (Q30276953) (← links)
- Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial (Q30407940) (← links)
- Update on the role of ipilimumab in melanoma and first data on new combination therapies (Q30585096) (← links)
- Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian cohort of the ipilimumab expanded access program (Q30746423) (← links)
- Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort (Q30828178) (← links)
- Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma (Q30839729) (← links)
- Ipilimumab treatment associated pituitary hypophysitis: clinical presentation and imaging diagnosis (Q30843026) (← links)
- Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma (Q30890582) (← links)
- Ipilimumab and craniotomy in patients with melanoma and brain metastases: a case series. (Q30901996) (← links)
- Evaluation Of 'Real-World' Ipilimumab Data In Ireland (Q31016577) (← links)
- Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphoma (Q33386521) (← links)
- Ipilimumab-induced thrombocytopenia in a patient with metastatic melanoma (Q33396455) (← links)
- Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy. (Q33396664) (← links)
- Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial (Q33402830) (← links)
- Ipilimumab-induced autoimmune pancytopenia in a case of metastatic melanoma (Q33415818) (← links)
- Ipilimumab-Induced Polyneuropathy; Ibuprofen-Induced Allergic-Type Liver Injury; Trimethoprim-Sulfamethoxazole-Induced Immune Thrombocytopenia in Children; Mesna-Induced Fixed Drug Eruption; Digoxin-Induced Ocular Toxicity (Q33435739) (← links)
- Correlation of clinical and immunological data in a metastatic melanoma patient with heterogeneous tumor responses to ipilimumab therapy (Q33522281) (← links)
- Anti-PD1 following ipilimumab for mucosal melanoma: durable tumor response associated with severe hypothyroidism and rhabdomyolysis (Q33551378) (← links)
- Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies (Q33572971) (← links)
- Ipilimumab treatment decreases monocytic MDSCs and increases CD8 effector memory T cells in long-term survivors with advanced melanoma (Q33591598) (← links)